Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Thyroid Gland Papillary Carcinoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Thyroid Gland Carcinoma (359
)
Thyroid Gland Anaplastic Carcinoma (70
)
Thyroid Gland Medullary Carcinoma (61
)
Thyroid Gland Follicular Carcinoma (25
)
Thyroid Gland Hurthle Cell Carcinoma (12
)
Thyroid Gland Carcinoma (359
)
Thyroid Gland Anaplastic Carcinoma (70
)
Thyroid Gland Medullary Carcinoma (61
)
Thyroid Gland Follicular Carcinoma (25
)
Thyroid Gland Hurthle Cell Carcinoma (12
)
›
Associations
(58)
News
Trials
Search handles
@AaronGoodman33
@VivekSubbiah
Search handles
@AaronGoodman33
@VivekSubbiah
Filter by
Latest
10ms
I had papillary thyroid carcinoma stage one..confined to thyroid wid no margins extending beyond thyroid..still this is third year and I am undergoing RAI whole body scan after alleviating tsh and then take RAI- 5MC, then scan. How long I would be on cancer radar (@palwaschaarbab)
10 months ago
10ms
Oncology master level board review! What do the following malignancies all have in common? @Dr_R_Kurzrock Mandibular ameloblastoma Hairy cell leukemia Melanoma Erdheim Chester disease Papillary thyroid cancer (@AaronGoodman33)
10 months ago
Review
10ms
BRAF mutation Seen in melanoma (40-60%) papillary thyroid carcinoma (45%), colonic adenocarcinoma (10-15%), hairy cell leukemia (~100%) lung adenocarcinoma, epithelioid glioblastoma, and hematologic malignancies, including hairy cell leukemia, LCH, ECD (@Sthanu5)
10 months ago
BRAF (B-raf proto-oncogene)
|
BRAF mutation
11ms
Good timing. Just did one this week for a papillary thyroid cancer arising from thyroglossal duct tissue. Locoregional metastatic disease to level 1 lymph nodes. Always fun. Great for the trainees to see! (@OSUEndoSurgBSM)
11 months ago
Metastases
over1year
#Thyroid GuidePx® was developed by Qualisure Diagnostics in Calgary, AB. The test is now available through Protean BioDiagnostics in Orlando, FL. https://t.co/RBmC11K7JC #americanmolecularpathology #AMP2022 #thyroidcancer #papillarythyroidcancer #thyca #cancer #oncology ()
over 1 year ago
Thyroid GuidePx®
over2years
🧬 #RET #precisionmedicine RET mutations👉 Germline events in hereditary MEN syndrome & somatic RET mutations sporadic MTC. RET fusions 👉 NSCLC 🫁, papillary thyroid cancer, many other cancers 🎯 @MCT_AACR @OncoAlert https://t.co/6WaGXXBTOj (@VivekSubbiah)
over 2 years ago
RET (Ret Proto-Oncogene)
|
RET fusion • RET mutation
over2years
⭐️RET gene alterations: RET mutations are seen as germline events in hereditary MEN syndrome and somatic RET mutations are seen in sporadic MTC. RET fusions are seen in NSCLC, papillary thyroid cancer, and many other cancers @MCT_AACR @RETpositive https://t.co/6WaGXXBTOj (@VivekSubbiah)
over 2 years ago
RET (Ret Proto-Oncogene)
|
RET fusion • RET mutation
over2years
RET fusions are seen in NSCLC (2%) and papillary thyroid cancers (PTC; 10%–20%), whereas somatic (60%–90%) or germline (100%) RET mutations are seen in medullary thyroid cancer (@VivekSubbiah)
over 2 years ago
RET (Ret Proto-Oncogene)
|
RET fusion • RET mutation
over2years
⭐️RET fusions➡️2% -lung cancer, ~20% papillary thyroid cancer, <1% multiple cancers. ⭐️RET mutations➡️Medullary thyroid cancer 60 % sporadic,100%hereditary #Selpercatinib & #Pralsetinib Selective RET inhibitors @trendscancer @CellPressNews https://t.co/cxDhYhMVce (@VivekSubbiah)
over 2 years ago
RET (Ret Proto-Oncogene)
|
RET fusion • RET mutation
|
Retevmo (selpercatinib) • Gavreto (pralsetinib)
over2years
🔺RET fusions👉 2% -lung cancer, ~20% papillary thyroid cancer, <1% multiple cancers. 🔺RET mutations👉Medullary thyroid cancer 60 % sporadic,100%hereditary 🔺#Selpercatinib & #Pralsetinib 👉selective RET inhibitors @trendscancer 🔺Questions for future https://t.co/cxDhYhMVce (@VivekSubbiah)
over 2 years ago
RET (Ret Proto-Oncogene)
|
RET fusion • RET mutation
|
Retevmo (selpercatinib) • Gavreto (pralsetinib)
over2years
⭐️RET fusions ➡️2% -lung cancer & ~20% papillary thyroid cancer & multiple cancers. ⭐️RET mutations➡️Medullary thyroid cancer 60 % sporadic,100%hereditary. ⭐️#Selpercatinib & #Pralsetinib are novel selective RET inhibitors @trendscancer #PrecisionMedicine https://t.co/cxDhYhMVce (@VivekSubbiah)
over 2 years ago
RET (Ret Proto-Oncogene)
|
RET fusion • RET mutation
|
Retevmo (selpercatinib) • Gavreto (pralsetinib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login